ADXS News and Press, Advaxis From 12/23/21

OTC Markets Group Welcomes Advaxis, Inc. to OTCQX PR Newswire NEW YORK , Dec. 23, 2021 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for over 11,000 U.S. and global securities, today announced Advaxis, I...

Advaxis (NASDAQ:ADXS) will begin trading on the OTCQX at market open on December 23 under the symbol ADXS. The company previously traded on Nasdaq. For further details see: Advaxis to start trading on OTCQX on Dec 23

MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has satisfied the requirements for trading of the Compa...

Updating the outcome of its second reconvened special meeting of stockholders, Advaxis (NASDAQ:ADXS) announced that the company’s investors approved its proposal for merger with Biosight by a clear majority of votes. However, a second proposal to authorize a reverse stock split —...

Stockholders approved Proposal 1 in support of Biosight merger Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved MONMOUTH JUNCTION, N.J., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinica...

Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation) Advaxis urges stockholders to vote “FOR” Proposal 2 at the upcoming special meeting in order to best position the company to build long term stockholder value MONMOUTH JUNCTION, N.J.,...

Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction Advaxis urges stockholders to vote “FOR” all of the proposals at the special meeting in order to best position the company to bui...

MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of proprietary Lm-based antigen delivery products, announ...

MONMOUTH JUNCTION, N.J., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today issued the following statement to stockholders: Dear Fellow Advaxis St...

MONMOUTH JUNCTION, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that leading independent proxy advisory firm, Glass Lewis & Co. (Gl...